Resources

Renalytix appoints Jean M. Casner as Director of Human Resources


[ad_1]

NEW YORK and SALT LAKE CITY, January 7, 2022 (GLOBE NEWSWIRE) – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announced today that Jean M. Casner joined the company this week on January 3, 2022 as Senior Vice President and Chief Human Resources Officer. Ms. Casner will be responsible for Renalytix’s global human resources organization, including HR strategy, compensation, benefits, learning and development, diversity and inclusion, and performance management. and talents.

Ms. Casner joins Renalytix from her former role as Senior Vice President and CHRO at Cantel Medical, which experienced significant annual revenue growth during her tenure prior to the recent acquisition of the company. During her time at Cantel, she made significant contributions to the company, including creating and implementing a comprehensive compensation and benefits strategy, developing and executing an updated annual incentive plan in as part of Cantel’s total rewards strategy and by implementing a global learning platform. Prior to Cantel, she held senior human resources roles with the National Basketball Association (NBA), Merck, The Dial Corporation (now owned by Henkel), Johnson and Johnson, and ORC (now owned by Mercer). Ms Casner succeeds Trent Bingham who left Renalytix on December 31, 2021.

With a long-standing focus and passion for healthcare, Ms. Casner has been recognized for her ability to grow businesses and implement strong training, learning and development strategies, putting the emphasis on employee engagement and transparent leadership.

“Defining and sustaining employee culture during a high growth phase is complex and absolutely critical to running the business,” said James McCullough, CEO of Renalytix. “Jean brings the wealth of experience that will allow Renalytix to expand the qualified staff needed to support our growing client base of partnerships with the healthcare system and their physicians and patients, as we continue to execute what we believe to be an expansion. business and significant revenue in the years to come.

About kidney disease
Kidney disease is now recognized as a public health epidemic affecting more than 850 million people worldwide. The Centers for Disease Control and Prevention (CDC) estimates that 15% of American adults, or 37 million people, currently have chronic kidney disease (CKD). Additionally, the CDC reports that 9 in 10 adults with CRF don’t know they have it and that one in two people with very poor kidney function who don’t have dialysis don’t know they have it. with CKD.1 Kidney disease is called the “silent killer” because it often has no symptoms and can go unnoticed until very late. Kidney disease kills more people every year than breast and prostate cancer.2 Every day, 13 patients in the United States die while waiting for a kidney transplant.3

About Renalytix
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the founder and global leader in the emerging field of biopronosticsMT for kidney health. The company has designed a new solution that successfully enables risk assessment of chronic kidney disease progression at an early stage. The company’s flagship product, KidneyIntelX, has received Breakthrough Designation from the United States Food and Drug Administration and is designed to help dramatically improve kidney disease prognosis, transplant management, clinical care, layering patients for clinical drug trials and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

About KidneyIntelX
KidneyIntelX is a one-of-a-kind solution that enables risk assessment of early stage diabetic kidney disease (DKD) progression by combining various data inputs, including validated blood biomarkers and personalized data from the patient’s health record. patient, and uses a proprietary algorithm to generate a unique risk score for the patient. This patient risk score predicts the progressive decline of renal function in DKD, allowing physicians and healthcare systems to optimize the allocation of treatment and clinical resources to patients most at risk.

Sources

1 https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
2 https://www.nicresearch.com/clinical-research-necessary-nephrology/
3 https://optn.transplant.hrsa.gov/

Forward-looking statements

Statements in this press release regarding matters which are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of such forward-looking statements include statements regarding: the potential benefits, including economic savings, of KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the business prospects of KidneyIntelX, if approved, including Understand whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to reduce the costs of chronic and end-stage renal disease, optimize delivery of care and improve outcomes. patient outcomes. Words such as “anticipates”, “believes”, “believes”, “expects”, “intention”, “plans”, “research” and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. All forward-looking statements are based on the current beliefs and assumptions of management and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on new artificial intelligence technologies which evolve rapidly and whose potential acceptance, usefulness and clinical practice remain uncertain; we only recently launched KidneyIntelX commercially; and risks related to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described in more detail in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our annual report on Form 20-F filed with the SEC. October 21, 2021, and other documents filed. we do with the SEC from time to time. All information in this press release is as of the date of publication, and we assume no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except if required by law.

Contact investors in the United Kingdom:
Walbrook PR Limited
Paul McManus / Lianne Applegarth
Tel: 020 7933 8780 or [email protected]
Mob: 07980 541 893/07584 391 303

Contact for US investors:
CapComm partners
Peter DeNardo
[email protected]
415-389-6400

Media contacts:
United States:
Chloe beaudoin
Renalytix
(207) 333-7947
[email protected]

Outside the United States:
Walbrook PR Limited
Paul McManus / Lianne Applegarth
Tel: 020 7933 8780 or [email protected]
Mob: 07980 541 893/07584 391 303

[ad_2]